Market reactionShares rose 12% on Nov 3.
enGene develops detalimogene, a non-viral gene therapy placed into the bladder for bladder cancer that no longer responds to BCG; it is not approved anywhere.
Detalimogene is a non-viral gene therapy for high-risk bladder cancer that no longer responds to BCG. In the 125-patient pivotal cohort, 54% had a complete response at some point. An estimated 25% of responders were still in response at 12 months, and recent patients responded less often. The company expects updated durability data and a pre-BLA meeting in the fourth quarter of 2026, then plans to start its BLA filing. It cut half its workforce in June; cash was $266.3 million at July 31.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Durability data support a filing
Do the updated data and FDA's feedback support filing a BLA on the single-arm LEGEND cohort?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Detalimogene's BLA rests on durability data still maturing in the pivotal cohort
BLA filing on single-arm CR data with a 25% 12-month KM estimate; approval hinges on whether FDA accepts durability as adequate
detalimogene's BLA path hinges on whether 12-month CR durability data satisfy FDA's threshold for bladder-sparing approval in BCG-unresponsive NMIBC with CIS
Detalimogene's BLA path in BCG-unresponsive NMIBC hinges on whether 25% 12-month KM durability clears the FDA's approvability bar
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.